保乳治疗后自体脂肪移植的肿瘤学安全性与监测
两组局部区域复发率均为5.6%(p=1.00),可触及肿块、脂肪坏死、钙化及活检指征均无显著差异,提示脂肪移植不干扰肿瘤学监测。
要点
- 保乳后延迟脂肪移植与对照组复发率均为5.6%,无显著差异。
- 脂肪坏死、可触及肿块、钙化及活检指征两组间均无显著差异。
- 脂肪移植未干扰保乳术后的肿瘤学随访监测。
核心结论
- 保乳治疗后延迟自体脂肪移植未增加局部区域复发率,且不干扰肿瘤学监测。
主要发现
- 两组中位年龄分别为50岁与51岁(p=0.87),BMI分别为28.2 kg/m²与27.2 kg/m²(p=0.38),随访时长分别为61.9个月与66.8个月(p=0.144)。
- 两组各4例复发(5.6%,p=1.00),累积发生率估计相似(log-rank检验,p=0.534)。
- 可触及肿块(9.7% vs 19.4%,p=0.1)、脂肪坏死(34.7% vs 33.3%,p=0.86)、钙化(37.5% vs 34.7%,p=0.73)、乳腺活检指征(15.3% vs 22.2%,p=0.23)均无显著差异。
临床怎么用
- 保乳治疗后延迟脂肪移植可考虑用于乳房重建辅助,无需担心增加复发或干扰影像监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Autologous fat grafting is a useful adjunct following breast reconstruction. The impact of autologous fat grafting on oncologic safety and surveillance remains questionable, particularly following breast conservation therapy. METHODS: The authors performed a retrospective review of patients who underwent delayed fat grafting following breast conservation therapy between 2006 and 2016. A control group of conservatively managed patients without grafting was matched for cancer stage, age, body mass index, and follow-up. Outcomes included locoregional recurrence and oncologic surveillance. RESULTS: Seventy-two patients were identified per cohort. There were no differences in median age (50 years versus 51 years; p = 0.87), body mass index (28.2 kg/m versus 27.2 kg/m; p = 0.38), or length of follow-up (61.9 months versus 66.8 months; p = 0.144) between controls and grafted patients, respectively. Overall, four patients in each cohort experienced recurrence (5.6 percent; p = 1.00) with similar cumulative incidence estimates observed (log-rank test, p = 0.534). There were no significant differences in palpable mass (9.7 percent versus 19.4 percent; p = 0.1), fat necrosis (34.7 percent versus 33.3 percent; p = 0.86), calcifications (37.5 percent versus 34.7 percent; p = 0.73), or indication for breast biopsy (15.3 percent versus 22.2 percent; p = 0.23) between breast conservation and breast conservation therapy plus autologous fat grafting cohorts, respectively. CONCLUSIONS: Overall, the authors found no difference in recurrence rates after breast conservation with or without delayed fat grafting. Furthermore, there were no differences in the rates of fat necrosis, palpable mass, and abnormal radiographic findings. This study represents the longest follow-up to date in in a large matched study of autologous fat grafting with breast conservation therapy demonstrating oncologic safety and no interference with follow-up surveillance. CLINICAL QUESTION/LEVEL OF EVIDENCE: Therapeutic, III.
引用
- Hanson SE, Kapur SK, Garvey PB, et al. Oncologic Safety and Surveillance of Autologous Fat Grafting following Breast Conservation Therapy. Plast Reconstr Surg. 2020. PMID: 32740564. doi:10.1097/PRS.0000000000006974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。